AREA PRESCRIBING COMMITTEE – Birmingham, Sandwell, Solihull and environs

Decision Making Support Tool

The following document supports the committee to consider formulary applications against defined criteria.

Formulary application reference:		APCBSSE/0036
Drug name and formulations:		Dulaglutide (Trulicity®)
Criteria	***Example***	**Committee Consensus**
Patient Safety	*Potential for abuse, toxicity, significant drug interactions*	Not significantly different to other GLP-1 agents, **but** no dosage adjustment is required in patients with mild or moderate renal impairment.
Clinical effectiveness	*Established licensed product*	Equivalent to other GLP-1s at licensed dose. Possibly better tolerated in terms of delivery device.
Strength of evidence		Strong evidence
Cost effectiveness or resource impact	*£*	Cost neutral
Place of therapy relative to available treatments	*1/2nd tier*	Equal with other GLP-1s
National guidance and priorities	*NICE, MTRAC*	NICE TA for other GLP-1s. NICE guideline 28 (Type 2 diabetes in adults: Management) covers use of GLP-1 as a class.
Local health priorities	*CCG views*	NOT as monotherapy as more cost-effective options available. Not in combination with insulin – local agreement with DMMAG that only lixisenatide should be used in combination with insulin. Role of GLP-1 is to reduce insulin doses.
Equity of access	*Equality assessment*	N/A
Stakeholder views	*Define wider groups to be engaged*	N/A
Implementation requirements	*Requires, RICAD ESCA etc.*	None

Decision Summary

Resubmission is recommended to complete the information to enable a decision:	
Not approved and rationale:	
Formulary status (RAG) and rationale	GREEN. However NOT for monotherapy, NOT in combination with insulin

Implementation requirements:	
Implementation monitoring:	